Protagonist Therapeutics Conference Call Summary Company Overview - **Company**: Protagonist Therapeutics (NasdaqGM:PTGX) - **Industry**: Biotechnology, specifically focused on peptide technology for drug development Key Points and Arguments 2026 Outlook - Protagonist Therapeutics is anticipating a significant year in 2026 with two potential FDA approvals for partnered products and ongoing data from its early pipeline [3][4] - The company has a strong financial position, funding new efforts with its own resources and maintaining a surplus cash balance, which will be used to maximize shareholder value [4] Product Pipeline - **IL-23 Receptor Antagonist**: Partnered with Johnson & Johnson (J&J), NDA filed in July 2025, with expected approval in Q3 2026 [4][5] - **Rusfertide (Hepcidin Mimetic)**: Partnered with Takeda, received priority review with NDA filed by the end of 2025, also expected approval in Q3 2026 [5][6] - The partnership with Takeda is structured as a 50-50 co-development and co-commercialization agreement, with an option for Protagonist to opt-in for a $400 million milestone payment [6][28] Market Potential - The oral IL-23 blocker is the first of its kind, with significant market potential as J&J's research indicates that over 75% of patients currently on injectables would switch to an oral option [14][15] - The company believes that the oral formulation could not only capture market share from injectables but also create a new market segment [15] Clinical Data and Efficacy - The company reported a 30% clinical remission rate in ulcerative colitis from phase two studies, indicating strong efficacy [17] - The mechanism of action targets the IL-23 receptor, which is overexpressed in gastrointestinal tissues, potentially leading to better outcomes in inflammatory bowel disease compared to existing treatments [19][20] Future Developments - Protagonist is advancing multiple assets, including oral IL-17 and oral hepcidin candidates, with phase one studies expected to yield important data [7][8][36] - The oral IL-17 candidate (PN-881) aims to achieve high potency and specificity, with a focus on both A and F isoforms, which is critical for efficacy in treating conditions like psoriasis [38][39] Strategic Considerations - The company is considering the balance between opting out of the rusfertide partnership for a substantial upfront payment versus co-promoting the drug, weighing the benefits of financial security against potential long-term gains [28][30] - Protagonist is also exploring the development of a franchise around IL-17 compounds, with a focus on psoriasis and potentially other indications [50][52] Competitive Landscape - The company acknowledges the competitive nature of the obesity and metabolic disease space, with plans to differentiate its oral triple G agonist from existing injectable options [54][55] - Protagonist aims to achieve both significant weight loss and improved safety profiles, positioning its products as versatile options for patients [59][60] Additional Important Insights - The company is committed to maintaining confidentiality around clinical data until strategic decisions are made, with plans to share findings at medical conferences rather than immediately [43] - Protagonist's approach to drug development emphasizes the advantages of peptides over small molecules, particularly in terms of potency and specificity [49] This summary encapsulates the key insights from the Protagonist Therapeutics conference call, highlighting the company's strategic direction, product pipeline, and market potential within the biotechnology sector.